JP7117323B2 - フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用 - Google Patents

フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用 Download PDF

Info

Publication number
JP7117323B2
JP7117323B2 JP2019557759A JP2019557759A JP7117323B2 JP 7117323 B2 JP7117323 B2 JP 7117323B2 JP 2019557759 A JP2019557759 A JP 2019557759A JP 2019557759 A JP2019557759 A JP 2019557759A JP 7117323 B2 JP7117323 B2 JP 7117323B2
Authority
JP
Japan
Prior art keywords
oxy
compound
isopropyl
triazol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019557759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517676A (ja
JP2020517676A5 (enExample
Inventor
テューダー・グレク
ジェイソン・グラント・ケトル
マーティン・ジョン・パッカー
スチュアート・エリック・ピアソン
ジェイムズ・マイケル・スミス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2020517676A publication Critical patent/JP2020517676A/ja
Publication of JP2020517676A5 publication Critical patent/JP2020517676A5/ja
Application granted granted Critical
Publication of JP7117323B2 publication Critical patent/JP7117323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019557759A 2017-04-27 2018-04-26 フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用 Active JP7117323B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490865P 2017-04-27 2017-04-27
US62/490,865 2017-04-27
PCT/EP2018/060800 WO2018197643A1 (en) 2017-04-27 2018-04-26 Phenoxyquinazoline compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2020517676A JP2020517676A (ja) 2020-06-18
JP2020517676A5 JP2020517676A5 (enExample) 2021-04-22
JP7117323B2 true JP7117323B2 (ja) 2022-08-12

Family

ID=62165533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557759A Active JP7117323B2 (ja) 2017-04-27 2018-04-26 フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用

Country Status (7)

Country Link
US (1) US11053223B2 (enExample)
EP (1) EP3615526B1 (enExample)
JP (1) JP7117323B2 (enExample)
CN (1) CN110546147B (enExample)
CA (1) CA3059660A1 (enExample)
ES (1) ES2887261T3 (enExample)
WO (1) WO2018197643A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190122433A (ko) * 2018-04-20 2019-10-30 엘지전자 주식회사 저온 저장고의 냉각 시스템

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018259078B2 (en) 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
KR102908062B1 (ko) * 2023-11-16 2026-01-05 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도
CN118772070B (zh) * 2024-06-12 2025-12-16 天津济坤医药科技有限公司 一种喹唑啉衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509499A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
MX2007004403A (es) * 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
CN1313449C (zh) * 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
CN104130200B (zh) * 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509499A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190122433A (ko) * 2018-04-20 2019-10-30 엘지전자 주식회사 저온 저장고의 냉각 시스템

Also Published As

Publication number Publication date
CA3059660A1 (en) 2018-11-01
JP2020517676A (ja) 2020-06-18
ES2887261T3 (es) 2021-12-22
WO2018197643A1 (en) 2018-11-01
EP3615526B1 (en) 2021-08-04
US11053223B2 (en) 2021-07-06
CN110546147B (zh) 2023-05-23
EP3615526A1 (en) 2020-03-04
US20200223828A1 (en) 2020-07-16
CN110546147A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
JP7128204B2 (ja) Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
JP5894714B1 (ja) 上皮成長因子受容体の活性化変異型のキナゾリン阻害剤
AU2014289762B2 (en) Protein tyrosine kinase modulators and methods of use
CN116096710A (zh) 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
JP6139792B2 (ja) タンキラーゼ阻害剤としてのピリド［２，３−ｄ］ピリミジン−４−オン化合物
AU2011311814A1 (en) Substituted pyridazine carboxamide compounds
US11053223B2 (en) Phenoxyquinazoline compounds and their use in treating cancer
WO2019196938A1 (zh) 喹唑啉类化合物作为egfr三突变抑制剂及其应用
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
BR112022024597B1 (pt) Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf, composições e usos dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220801

R150 Certificate of patent or registration of utility model

Ref document number: 7117323

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250